Escolar Documentos
Profissional Documentos
Cultura Documentos
TRATAMENTO DA DOENÇA DE
ALZHEIMER
JÚLIA CUNHA
LOUREIRO
MARCOS
VASCONCELOS
PAIS
ORESTES
VICENTE
FORLENZA
INTRODUÇÃO
OBJETIVOS
NEUROPATOLOGIA
LEMBRAR
LEMBRAR
LEMBRAR
LEMBRAR
NEUROIMAGEM
BIOMARCADORES PLASMÁTICOS
LEMBRAR
Depressão
LEMBRAR
Agitação
TRATAMENTO FARMACOLÓGICO
Sintomáticos
Anticolinesterásicos
LEMBRAR
Memantina
LEMBRAR
LEMBRAR
Antipsicóticos
LEMBRAR
LEMBRAR
A maior parte dos ensaios clínicos realizados nos últimos anos testou a
patologia amiloide como alvo preferencial dos fármacos desenvolvidos.
Admite-se hoje, porém, que a combinação de alvos moleculares e de
intervenções mais precoces sejam necessárias para o sucesso de novos
ensaios clínicos.
CONCLUSÃO
1. Nitrini R, Bottino CMC, Albala C, Custodio Capuñay NS, Ketzoian C, Llibre Rodriguez J, et
al. Prevalence of dementia in Latin America: a collaborative study of population-based
cohorts. Int Psychogeriatrics. 2009 Aug 1;21(4):622–30.
https://doi.org/10.1017/S1041610209009430
2. Atri A. The alzheimer’s disease clinical spectrum: diagnosis and management. Med Clin
North Am. 2019 Mar;103(2):263–93. https://doi.org/10.1016/j.mcna.2018.10.009
4. Alzheimer’s Association. 2018 alzheimer’s disease facts and figures: includes a special
report on the financial and personal benefits of early diagnosis. Alzheimers Dement
2018;14(3):367–429. https://doi.org/10.1016/j.jalz.2018.02.001
5. Hardy J, Higgins G. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992
Apr;256(5054):184–5. https://doi.org/10.1126/science.1566067
6. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and
biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med.
2012;367(9):795–804. https://doi.org/10.1056/NEJMoa1202753
7. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The
diagnosis of dementia due to Alzheimer’s disease: recommendations from the National
Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement. 2011 May;7(3):263–9.
https://doi.org/10.1016/j.jalz.2011.03.005
10. Hardy J, Selkoe DJ. The amyloid hypothesis of alzheimer’s disease: progress and
problems on the road to therapeutics. Science. 2002 Jul;297(5580):353–6.
https://doi.org/10.1126/science.1072994
11. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO
Mol Med. 2016 Jun;8(6):595–608. https://doi.org/10.1126/science.1072994
12. Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease
pathogenesis. Biol Psychiatry. 2015 Jan;77(1):43–51.
https://doi.org/10.1016/j.biopsych.2014.05.006
13. Scheltens P, Blennow K, Breteler MMB, Strooper B, Frisoni GB, Salloway S, et al.
Alzheimer’s disease. Lancet. 2016 Jul;388(10043):505–17.
https://doi.org/10.1016/j.biopsych.2014.05.006
14. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human
apoE isoforms differentially regulate brain amyloid- peptide clearance. Sci Transl Med.
2011 Jun;3(89):89ra57. https://doi.org/10.1126/scitranslmed.3002156
15. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and
Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011
Sep;16(9):903–7. https://doi.org/10.1038/mp.2011.52
16. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining
the preclinical stages of alzheimer’s disease: recommendations from the National Institute
on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for alzheimer’s
disease. Alzheimer’s Dement. 2011 May;7(3):280–92.
https://doi.org/10.1016/j.jalz.2011.03.003
17. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical
Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimer’s
Dement. 2016 Mar;12(3):292–323. https://doi.org/10.1016/j.jalz.2016.02.002
18. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive
impairment. Arch Neurol. 1999 Mar;56(3):303–8.
https://doi.org/10.1001/archneur.56.6.760
19. Petersen RC. Mild cognitive impairment. Contin Lifelong Learn Neurol. 2016
Apr;22(2):404–18. https://doi.org/10.1212/CON.0000000000000313
20. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence
and classification of mild cognitive impairment in the cardiovascular health study cognition
study. Arch Neurol. 2003 Oct;60(10):1385–9. https://doi.org/10.1001/archneur.60.10.1385
21. Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al. Prevalence
of mild cognitive impairment is higher in men: the mayo clinic study of aging. Neurology.
2010 Sep;75(10):889–97. https://doi.org/10.1212/WNL.0b013e3181f11d85
23. Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The clinical use of structural
MRI in Alzheimer disease. Nat Rev Neurol. 2010 Feb;6(2):67–77.
https://doi.org/10.1038/nrneurol.2009.215
24. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of
medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing:
diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992
Oct;55(10):967–72. https://doi.org/10.1136/jnnp.55.10.967
25. Scheltens P, Launer LJ, Barkhof F, Weinstein HC, Gool WA. Visual assessment of medial
temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol.
1995 Sep;242(9):557–60. https://doi.org/10.1007/BF00868807
26. Korf ESC, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI
predicts dementia in patients with mild cognitive impairment. Neurology. 2004
Jul;63(1):94–100. https://doi.org/10.1212/01.wnl.0000133114.92694.93
27. Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, et al.
Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol. 2011
Dec;21(12):2618–25. https://doi.org/10.1007/s00330-011-2205-4
28. Lehmann M, Koedam ELGE, Barnes J, Bartlett JW, Ryan NS, Pijnenburg YAL, et al.
Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in
pathologically-confirmed alzheimer’s disease. Neurobiol Aging. 2012 Mar;33(3):627.e1-
627–.e12. https://doi.org/10.1016/j.neurobiolaging.2011.04.003
29. Herholz K, Ebmeier K. Clinical amyloid imaging in alzheimer’s disease. Lancet Neurol.
2011 Jul;10(7):667–70. https://doi.org/10.1016/S1474-4422(11)70123-5
30. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al.
Prevalence of cerebral amyloid pathology in persons without dementia. JAMA. 2015
May;313(19):1924–38. https://doi.org/10.1001/jama.2015.4668
31. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging
results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.
Neurobiol Aging. 2010 Aug;31(8):1275–83.
https://doi.org/10.1016/j.neurobiolaging.2010.04.007
32. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of
alzheimer disease neuropathologic changes with cognitive status: a review of the literature.
J Neuropathol Exp Neurol. 2012 May;71(5):362–81.
https://doi.org/10.1097/NEN.0b013e31825018f7
33. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress
and future directions. Lancet Neurol. 2015 Jan;14(1):114–24.
https://doi.org/10.1016/S1474-4422(06)70355-6
35. Diniz BSO, Pinto JA, Forlenza OV. Do CSF total tau, phosphorylated tau, and β-amyloid
42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A
systematic review and meta-analysis of the literature. World J Biol Psychiatry. 2008
Jan;9(3):172–82. https://doi.org/10.1080/15622970701535502
36. Forlenza OV, Radanovic M, Talib LL, Aprahamian I, Diniz BS, Zetterberg H, et al.
Cerebrospinal fluid biomarkers in alzheimer’s disease: diagnostic accuracy and prediction
of dementia. Alzheimers Dement (Amst). 2015 Oct;1(4):455–63.
https://doi.org/10.1016/j.dadm.2015.09.003
37. Henriksen K, O’Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, et al. The
future of blood-based biomarkers for alzheimer’s disease. Alzheimer’s Dement. 2014
Jan;10(1):115–31. https://doi.org/10.1016/j.jalz.2013.01.013
38. Blennow K. A review of fluid biomarkers for alzheimer’s disease: moving from csf to
blood. Neurol Ther. 2017 Jul;6(S1):15–24. https://doi.org/10.1007/s40120-017-0073-9
39. Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, et al. Plasma
biomarkers of ad emerging as essential tools for drug development: an EU/US CTAD Task
Force Report. J Prev Alzheimer’s Dis. 2019;6(3):169–73.
https://doi.org/10.14283/jpad.2019.21
40. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA
research framework: toward a biological definition of alzheimer’s disease. Alzheimer’s
Dement. 2018 Apr;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018
41. Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: an
unbiased descriptive classification scheme for alzheimer disease biomarkers. Neurology.
2016 Aug;87(5):539–47. https://doi.org/10.1212/WNL.0000000000002923
42. Feldman HH, Lane R. Rivastigmine: a placebo controlled trial of twice daily and three
times daily regimens in patients with alzheimer’s disease. J Neurol Neurosurg Psychiatry.
2007 Oct;78(10):1056–63. https://doi.org/10.1136/jnnp.2006.099424
43. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and
behavioral disturbances in dementia: findings from the cache county study on memory in
aging. Am J Psychiatry. 2000 May;157(5):708–14.
https://doi.org/10.1176/appi.ajp.157.5.708
44. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and
psychological symptoms of dementia. BMJ. 2015 Mar;350:h369.
https://doi.org/10.1136/bmj.h369
45. Oliveira AM, Radanovic M, Homem de Mello PC, Buchain PC, Dias Vizzotto A, Harder J,
et al. An intervention to reduce neuropsychiatric symptoms and caregiver burden in
dementia: preliminary results from a randomized trial of the tailored activity program-
outpatient version. Int J Geriatr Psychiatry. 2019 Sep;34(9):1301–7.
https://doi.org/10.1002/gps.4958
46. Gitlin LN, Arthur P, Piersol C, Hessels V, Wu SS, Dai Y, et al. Targeting behavioral
symptoms and functional decline in dementia: a randomized clinical trial. J Am Geriatr Soc.
2018 Feb;66(2):339–45. https://doi.org/10.1111/jgs.15194
47. Epperly T, Dunay MA, Boice JL. Alzheimer disease: pharmacologic and
nonpharmacologic therapies for cognitive and functional symptoms. Am Fam Physician.
2017 Jun;95(12):771–8.
48. Dyer SM, Harrison SL, Laver K, Whitehead C, Crotty M. An overview of systematic
reviews of pharmacological and non-pharmacological interventions for the treatment of
behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2018
Mar;30(3):295–309. https://doi.org/10.1017/S1041610217002344
49. Forlenza OV, Loureiro JC, Pais MV, Stella F. Recent advances in the management of
neuropsychiatric symptoms in dementia. Curr Opin Psychiatry. 2017 Mar;30(2):151–8.
https://doi.org/10.1097/YCO.0000000000000309
50. Chi S, Wang C, Jiang T, Zhu X-C, Yu J-T, Tan L. The prevalence of depression in
Alzheimer’s disease: a systematic review and meta-analysis. Curr Alzheimer Res.
2015;12(2):189–98. https://doi.org/10.2174/1567205012666150204124310
51. Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. The prevalence of
neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J
Affect Disord. 2016 Jan;190:264–71. https://doi.org/10.1016/j.jad.2015.09.069
52. Pink A, Stokin GB, Bartley MM, Roberts RO, Sochor O, Machulda MM, et al.
Neuropsychiatric symptoms, APOE 4, and the risk of incident dementia: a population-based
study. Neurology. 2015 Mar;84(9):935–43.
https://doi.org/10.1212/WNL.0000000000001307
53. Lanctôt KL, Agüera-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, et al. Apathy
associated with neurocognitive disorders: recent progress and future directions.
Alzheimer’s Dement. 2017 Jan;13(1):84–100. https://doi.org/10.1016/j.jalz.2016.05.008
56. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral
symptoms in dementia. JAMA. 2012 Nov;308(19):2020–9.
https://doi.org/10.1001/jama.2012.36918
58. Schneider LS. Alzheimer disease pharmacologic treatment and treatment research.
Continuum. 2013 Apr;19(2):339–57.
https://doi.org/10.1212/01.CON.0000429180.60095.d0
60. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for
agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011 Feb;85(1):20–2.
https://doi.org/10.1002/14651858.CD008191.pub2
61. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical
symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1
outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008 Jul;165(7):844–54.
https://doi.org/10.1176/appi.ajp.2008.07111779
62. Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, et al. Relapse
risk after discontinuation of risperidone in alzheimer’s disease. N Engl J Med. 2012
Oct;367(16):1497–507. https://doi.org/10.1056/NEJMoa1114058
63. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al.
Antipsychotics, other psychotropics, and the risk of death in patients with dementia. JAMA
Psychiatry. 2015 May;72(5):438–45. https://doi.org/10.1001/jamapsychiatry.2014.3018
64. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug
treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA.
2005 Oct;294(15):1934–43. https://doi.org/10.1001/jama.294.15.1934
65. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics
Society 2019 Updated AGS Beers CriteriaVR for potentially inappropriate medication use in
older adults. J Am Geriatr Soc. 2019;67(4):674–94. https://doi.org/10.1111/jgs.15767
66. Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in
Alzheimer’s disease. BMC Med. 2010 Dec;8(1):89.
Loureiro JC, Pais MV, Forlenza OV. Atualização do diagnóstico e do tratamento da doença de
Alzheimer. In: Associação Brasileira de Psiquiatria; Nardi AE, Silva AG, Quevedo JL,
organizadores. PROPSIQ Programa de Atualização em Psiquiatria: Ciclo 9. Porto Alegre: Artmed
Panamericana; 2020. p. 119–50.